conclusions association with sex, genotype and clinical symptoms revealed that the pre-s1 orf deletion occurred in 40% , 40%,and 20% of genotypes b,c, and d respectively, and 80% of the female population, of which all but one were diagnosed with chronic hepatitis b. additionally, several mutations were found in the bcp region with the following incidence rate; c1653 t (8.6%), a1752 g (10.8%),17...

Introduction: The hepatitis B is a viral infection that causes a big problem globally. About 2 billion people worldwide are infected and there are now about 400 million HBV-DNA carriers around the world. HBV infection is the ninth cause of death worldwide and infects about 350 million new cases each year in the world. HBV-DNA can be spotted in different body secretions and fluids, including se...

Chronic hepatitis B virus (HBV) infection is caused by inadequate anti-viral immunity. Activation of plasmacytoid dendritic cells (pDC) leading to IFNα production is important for effective anti-viral immunity. Hepatitis B virus (HBV) infection lacks IFNα induction in animal models and patients and chronic HBV patients display impaired IFNα production by pDC. Therefore, HBV and HBV-derived prot...

Chronic hepatitis B (CHB), caused by persistent virus (HBV) infection, significantly increases the risk of leading to liver diseases. Despite successful development and implementation HBV prophylactic vaccines for several decades, therapeutic vaccine, a substantially potential strategy eradicate achieve CHB cure, remains great challenge. Herein, we applied flash nanocomplexation (FNC) technolog...

Chronic hepatitis B virus (HBV) infection can lead to liver cirrhosis and hepatocellular carcinoma. HBV reactivation during or after chemotherapy is a potentially fatal complication for cancer patients with chronic HBV infection. Transcription of HBV is a critical intermediate step of the HBV life cycle. However, factors controlling HBV transcription remain largely unknown. Here, we found that ...

BACKGROUND Currently, no licensed therapy can thoroughly eradicate hepatitis B virus (HBV) from the body, including interferon α and inhibitors of HBV reverse-transcription. Small interfering RNA (siRNA) seem to be a promising tool for treating HBV, but had no effect on the pre-existing HBV covalently closed circular DNA. Because it is very difficult to thoroughly eradicate HBV with unique siRN...

conclusions: premature stop codon in the s gene was observed in all countries with evaluable hbv genome sequences. co-existence of detectable hepatitis b surface antigen (hbsag) and s gene premature stop codon was inconsistent with other studies. investigations on yield truncated hbsag are suggested to determine if they can affect elisa hbsag results. background: we have previously reported on ...

objective: despite availability of an effective vaccine against hepatitis b virus (hbv), the global prevalence of this virus infection has not diminished significantly. contrary to numerous other human viruses, hbv does not have the ability to propagate in cell culture. however, infectious virus has been produced by transfection of human hepatoma cells with plasmids that contain full length hbv...

    Background: Hepatitis B Virus (HBV) causes acute and chronic liver disease worldwide. HBV has eight genotypes (A to H) which is the reflection of its genome with their characteristic geographical distribution. Each genotype could have different pathogenic and therapeutic characteristics. There have been few records on HBV genotyping in general population from our region. This study aimed to...